A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer

NCT04934618 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

85

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: Carelizumab Combined With Irinotecan and Apatinib

Sponsor

Nanfang Hospital, Southern Medical University